Join
Live feed
·
PRReleasevia Quantisnow
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

ByQuantisnow·Wall Street's wire, on your screen.
FHTX· Foghorn Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FHTX (Foghorn Therapeutics Inc.) and more on Quantisnow.